Clinical trials: Urinary System Tumor
Carcinoma, Renal Cell, Carcinoma, Renal Cell (Advanced)
Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar
Renal cell carcinoma accounts for roughly 3 % of all cancer. It is a rather aggressive cancer type, which means that patients who present with an advanced disease have a rather poor prognosis.
- Trial name
- NCT00895674
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 18 sites in Argentina, Austria and 16 more
- Volunteers
- 2,840 people
- Sponsor
- Bayer
Metastatic Urothelial Cancer
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
This is a global, multicenter, randomized, open-label study. The main objective of the study is to measure the clinical activity and safety of zelenectide pevedotin formally BT8009, in combination with pembrolizumab versus…
- Trial name
- NCT06225596
- Testing
- Zelenectide pevedotin, Pembrolizumab, Gemcitabine + cisplatin Or carboplatin
- Where
- 102 sites in United States, Argentina and 19 more
- Volunteers
- 375 people
- Sponsor
- BicycleTx Limited
Bladder Cancer
Treatment of High-risk Non-muscle Invasive Bladder Cancer With IMUNO BGC Moreau RJ as Prophylaxis
Bladder cancer is the fourth reason of neoplasia in our environment, there are 25 new cases diagnosed per 100,000 inhabitants each year.
- Trial name
- NCT03982797
- Testing
- Instillation of IMUNO BCG Moreau RJ
- Where
- 15 sites in Spain
- Volunteers
- 306 people
- Sponsor
- Biofabri, S.L
Bladder Cancer
AD 32 With or Without BCG After Surgery in Treating Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Biological therapies such as BCG use different ways to stimulate the immune system and stop cancer cells from…
- Trial name
- NCT00003759
- Testing
- BCG vaccine, valrubicin, conventional surgery
- Where
- United States
- Sponsor
- Anthra Pharmaceuticals
Metastatic Renal Cell Carcinoma
Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma
This study will evaluate the safety and efficacy of Dovitinib versus sorafenib in patients with metastatic renal cell cancer.
- Trial name
- NCT01223027
- Testing
- Dovitinib, Sorafenib
- Where
- 199 sites in United States, Argentina and 25 more
- Volunteers
- 564 people
- Sponsor
- Novartis Pharmaceuticals
Bladder Cancer
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
Researchers are looking for new ways to treat people with urothelial cancer (UC) that is locally advanced or metastatic. The standard treatment for locally advanced or metastatic UC is enfortumab vedotin (EV) given with…
- Trial name
- NCT07232602
- Testing
- MK-3120, EV, Pembrolizumab
- Where
- 17 sites in United States, Chile and 6 more
- Volunteers
- 55 people
- Sponsor
- Merck Sharp & Dohme LLC
Metastatic Urothelial Carcinoma, Urothelial Carcinoma
N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer
This phase Ib trial will investigate the effect of N-803 in combination with pembrolizumab and enfortumab vedotin in treating participants with urothelial cancer that has spread to nearby tissue or lymph nodes (locally advanced)…
- Conditions
- Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Urothelial Cancer
- Trial name
- NCT07217496
- Testing
- Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- ImmunityBio, Inc.
Non-small Cell Lung Cancer, Melanoma
A First-in-human (FIH) Combination Treatment Study With a Single Dose Level of BMC128
The purpose of this study is to assess the safety and tolerability of BMC128 in combination with nivolumab (a known immunotherapy) in order to investigate if administration of select elements of the intestinal microbiome may…
- Conditions
- Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
- Trial name
- NCT05354102
- Testing
- BMC128, Nivolumab
- Where
- Israel
- Volunteers
- 11 people
- Sponsor
- Biomica Ltd.
Urothelial Carcinoma
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
This study was conducted to examine survival, disease-free survival, safety, and the magnitude of the immune response induced following administration of DN24-02 in subjects with HER2+ urothelial carcinoma.
- Trial name
- NCT01353222
- Testing
- DN24-02, Standard of Care
- Where
- 60 sites in United States
- Volunteers
- 142 people
- Sponsor
- Dendreon
Metastases, Neoplasm, Carcinoma, Non-small Cell Lung
A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors
Study I3G-MC-JGCB (JGCB) is a multicenter, nonrandomized, open-label, dose-escalation Phase 1b study of LY2584702 in combination with either erlotinib or everolimus.
- Conditions
- Metastases, Neoplasm, Carcinoma, Non-small Cell Lung, Renal Cell Carcinoma, Neuroendocrine Tumors
- Trial name
- NCT01115803
- Testing
- LY2584702, Erlotinib, Everolimus
- Where
- 3 sites in United States, France
- Volunteers
- 29 people
- Sponsor
- Eli Lilly and Company
Renal Cell Carcinoma, Non-hodgkin's Lymphoma
Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
The purpose of this study is to determine if MDX-1203 is safe for the treatment of renal cell carcinoma or non-hodgkin's lymphoma.
- Trial name
- NCT00944905
- Testing
- MDX-1203
- Where
- 5 sites in United States
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Renal Cell Carcinoma
Cost Effectiveness Of Sunitinib In Central America And Caribbean
Primary Hypothesis: The therapy with Sunitinib represents better cost-effectiveness than IFN-α in first-line treatment for metastatic Renal Cell Carcinoma (mRCC) in Central America and Caribbean countries
- Trial name
- NCT01033981
- Testing
- Sunitinib
- Where
- Panama
- Volunteers
- 4 people
- Sponsor
- Pfizer
Bladder Cancer
Detection of Bladder Tumors After 30 Min Instillation of Hexvix
The objective of the study is to compare Hexvix® flexible cystoscopy and white light flexible cystoscopy in the detection of histological confirmed bladder tumor lesions defined as dysplasia; CIS; Ta; T1; and ≥ T2 after 30…
- Trial name
- NCT01551407
- Testing
- Hexvix
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Photocure
Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
The main purpose of this study is to determine the safety, tolerability (how the body reacts to the drug[s]) and effectiveness (ability to treat the cancer) of REGN5678 (Nezastomig) alone, or in combination with cemiplimab.
- Trial name
- NCT03972657
- Testing
- REGN5678, Cemiplimab
- Where
- 27 sites in United States, South Korea
- Volunteers
- 345 people
- Sponsor
- Regeneron Pharmaceuticals
Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
This is a Phase 1/2, open-label, dose-exploration, combination/expansion study, which will start by evaluating the safety and tolerability of NTX-301, an oral DNMT1 inhibitor, as a monotherapy in patients with advanced solid…
- Conditions
- Advanced Solid Tumor, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Urothelial Carcinoma, High-grade Glioma
- Trial name
- NCT04851834
- Testing
- NTX-301, Platinum-based Chemotherapy, Temozolomide
- Where
- 2 sites in Australia
- Volunteers
- 12 people
- Sponsor
- Xennials Therapeutics Australia Pty Ltd
Breast Neoplasm, Pancreatic Neoplasm
Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2
The purpose of this study is to investigate a safe dose of TAK-165, once daily (QD), in patients with HER2-tumor expression.
- Conditions
- Breast Neoplasm, Pancreatic Neoplasm, Lung Neoplasm, Ovarian Neoplasm
- Trial name
- NCT00034281
- Testing
- TAK-165
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- Takeda
Pleural Effusion, Malignant, Ascites, Malignant
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations…
- Conditions
- Pleural Effusion, Malignant, Ascites, Malignant, Carcinoma, Carcinoma, Hepatocellular
- Trial name
- TraveraRTGx (NCT05461430)
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Travera Inc
Carcinoma, Renal Cell
Study Of Safety And Tolerability Of GW786034 Given With Lapatinib In Cancer Patients
This Phase I, dose finding study evaluates the safety and tolerability of lapatinib, a dual tyrosine kinase inhibitor, and GW786034, an anti-angiogenesis agent, when given together.
- Trial name
- NCT00158782
- Testing
- GW786034, lapatinib
- Where
- 2 sites in United States, Netherlands
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
Renal Cell Carcinoma
Axitinib Therapy Management Study
The objectives of the study is to describe axitinib therapy management through use of the data to be generated by ConcertAI
- Trial name
- NCT04555603
- Testing
- Inlyta, Bavencio, Keytruda
- Where
- United States
- Sponsor
- Pfizer
Solid Tumor, Colon Carcinoma
PET-imaging of Two Vartumabs in Patients With Solid Tumors
VARTUTRACE is a first-in-human PET/CT molecular imaging study in patients with solid tumors. This study will investigate the biodistribution and pharmacology of two antibody fragments binding oncofetal Chondroitin Sulfate (CS).
- Conditions
- Solid Tumor, Colon Carcinoma, Rectal Carcinoma, Osteosarcoma
- Trial name
- VARTUTRACE (NCT06645808)
- Testing
- 89Zr-DFO-N-Suc-F8scFv, 89Zr-DFO-N-Suc-C9scFv, PET/CT scan
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Var2 Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.